Yan CV, 08-6-2014

1

CURRICULUM VITAE

Jun Yan, M.D., Ph.D. Home address: 4808 Cedar Forest Place, Louisville, KY 40245

Tel: (502) 852-3628 (O), (502) 852-7168 (L) 852-5357 (L) Fax: (502) 852-2123

Email: jun.yan@louisville.edu

EDUCATION 07/1997: Ph. D. - Immunology - Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine 07/1991: M. S. - Immunology - Department of Microbiology and Immunology, Nanjing Medical University 07/1985: M.D. – Jiangsu University School of Medicine

ACADEMIC APPOINTMENTS 08/1997 ~ 01/1999: Postdoctoral Fellow, Department of Pathology, University of Louisville, Louisville, KY 02/1999 ~ 01/2002: Research Associate, Department of Internal Medicine, Yale University, New Haven, CT 02/2002 ~ 12/2002: Associate Research Scientist – Section of Rheumatology, Department of Internal Medicine, Yale University, New Haven, CT 01/2003 ~ 06/2008: Assistant Professor, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, KY 07/2008 ~ 06/2012: Associate Professor with tenure, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, KY 2011: Co-Director, Tumor Immunobiology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 03/2012: Endowed Chair in Translational Research, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 07/2012: Professor of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, KY

Yan CV, 08-6-2014

2

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES 1997, Clinical Immunology Society 2000, American Association of Immunologists 2003, American Association for Cancer Research 2003, Research Member of American College of Rheumatology 2014, American Society of Hematology

HORNORS and AWARDS

1996: Third prize winner of dissertation in The Advanced Course and Symposium in Immunology organized by IUIS. Beijing, China 1998: New Investigators Award by CIS (Clinical Immunology Society) 2002-2006: Career Development Award, S.L.E Foundation 2003: AAI Junior Faculty Travel Award 2003-2009: American College of Rheumatology Investigator Award 2003: Roger Herzig Junior Faculty Research Prize (University of Louisville) 2006: NIH TTT study section ad hoc member 2008: Reviewer, Arthritis Foundation Clinical Immunology Study Section 2008: Outstanding Investigator Award, Department of Medicine, University of Louisville 2009: NIH TTT study section ad hoc member, NIH CII study section ad hoc member 2009-2013: American Cancer Society Research Scholar Grant 2010: DOD IMM-1 study section member 2010: NIH RC4 study section member 2010: Julep Ball Scientist of the Year, James Graham Brown Cancer Center, University of Louisville 2011: Grant Reviewer, Association for International Cancer Research, UK 2012: Grant Reviewer, Austria Science Fund 2013: Reviewer, Hollings Cancer Center Pilot Project 2013: Reviewer, Czech Science Foundation 2014: Reviewer, National Psoriasis Foundation 2014: NIH/NIDCR Special Emphasis Panel ZDE1VH07 study section member 2010-2014: Regular member, NIH TTT study section

COMMITTEE:

2011-present: T32 Training Program in Transplantation Executive Committee member 2011-present: James Graham Brown Cancer Center Executive Committee member

Scientific Advisory Board: 2006- present: Scientific Advisory Board member, Biothera Inc., Eagen, MN

AWARDS FROM TRAINEES:

Yan CV, 08-6-2014

3

Stephanie Wagner, MD: First Place in Research!Research (Clinical Fellow) Best fellow presenter at the Southern Society of Clinical Investigation (New Orleans), 2007 Michael Driscoll, MD: Associates Research Poster prize at ACP (American College of Physicians) meeting in San Diego, 2007 Chuanlin Ding, Ph.D: Second place, James Graham Brown Cancer Center Annual Research Retreat, 2008 Dong Xiang, M.D: First Place in Research!Research (Clinical Fellow), 2009 First place, James Graham Brown Cancer Center Annual Research Retreat, 2009 Merit Award, 2011 Breast Cancer Symposium, San Francisco, CA Yunfeng Ma, Ph.D. First place, James Graham Brown Cancer Center Annual Research Retreat, 2011 Chris Fleming, M.D./Ph.D. candidate First place, Basic Science Doctoral Graduate Student Research Prize, Research!Louisville, 2013 First place, JG Brown Cancer Center Annual Research Retreat, 2013 First place, Midwest Regional American Physician Scientists Association Meeting Sabrin Albeituni, Ph.D. Candidate Michael Tanner Memorial Award for Graduate Student Research!Louisville, 2013 Sabrin Albeituni, Ph.D. Candidate First place, JG Brown Cancer Center Annual Research Retreat, 201

EDUCATIONAL ACTIVITIES

1997 – 1991: Course teaching: Basic Immunology and Tumor Immunobiology medical school students, Jiangsu University School of Medicine Role: Course Director. 30 courses, 200 students each year 2003: Cellular and Molecular Immunology for Graduate Students, Department of Microbiology and Immunology, University of Louisville

Yan CV, 08-6-2014

4

Role: Lecturer. 4 courses, 12 students 2004: Cellular and Molecular Immunology for Medical School Students and Graduate Students, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 4 courses, 12 students 2005: Medical Microbiology and Immunology for medical school students, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 100 students Spring, 2006: Chinese Academy of Sciences. BIO2000 Role: Lecturer. 2 courses, 150 students Spring, 2006: Beijing University, China. BIO2000 Role: Lecturer. 2 courses, 150 students Fall, 2006: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 100 students Spring, 2007: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 4 courses, 12 students August 21, 2007: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 120 students Fall, 2007: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 10 students Spring, 2008: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Course Director and Lecturer. 1 course, 8 students September 4, 2008: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 100 students Spring, 2009: Advance Immunology, University of Louisville B Cells and Autoimmunity Role: Lecturer. 3 courses, 11 students

Yan CV, 08-6-2014

5

September 22, 2009: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 120 students Fall, 2009: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 11 students Spring, 2010: Advance Immunology, University of Louisville B Cells and Autoimmunity Role: Lecturer. 3 courses, 10 students September, 2010: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 140 students Fall, 2010: Advance Immunology, Department of Microbiology and Immunology, University of Louisville Role: Lecturer. 3 courses, 7 students Spring, 2011: Advance Immunology, University of Louisville B Cells and Autoimmunity Role: Lecturer. 3 courses, 8 students September, 2011: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 2 courses, 140 students September, 2012: Medical Microbiology and Immunology, University of Louisville Role: Lecturer. 1 course, 140 students November, 2013: Advance Immunology, University of Louisville Role: Lecturer. 1 course, 2 students.

GRANTS AND CONTRACTS: Active funding:

PI: J. Yan (NIH P01CA163223-01A1, Co-PI and PI on Project#2) 03/01/2013 to 2/28/2018 20% effort $1.46 million/year Overall Title: Systems Biochemistry in Lung Cancer: Toward A Mechanistic Understanding of NSCLC

Yan CV, 08-6-2014

6

Project#2: Determining Tumor Metabolism and Biochemical Mechanisms of β-Glucan Action in Mice The major goal of this proposal is to investigate how β-glucan treatment influences the metabolic profiles of tumor-infiltrating immune cells and subsequent tumor cell metabolism using lung carcinoma models.

PI: J. Yan 08/01/09 to 7/31/2015 NCI/NIH R01CA150947 20% effort $1,000,000 Title: Mechanisms of Immune Modulation Mediated by Yeast-derived Particulate Beta-Glucan The major goal of this proposal is to understand the cellular and molecular mechanism of action of yeast-derived particulate β-glucans in cancer biology and therapy. PI: J. Yan 05/01/2012 to 06/30/2015 National Psoriasis Foundation $200,000 Title: Regulation of Psoriasis Pathogenesis by IL-1β Signaling Pathway The major goal of this proposal is to understand how IL-1β signaling pathway regulates dermal γδ T cell activation and IL-17 production.

COMPLETED:

PI: J. Yan RSG-09-190-01-LIB 07/01/09 to 6/30/14 American Cancer Society 15% effort $600,000 Title: Targeting of Antigen to B Cells as a Novel Vaccine for Cancer Immunotherapy The major goal of this proposal is to develop a CD19 miniantibody fusion protein with tumor associate antigen Her-2/neu for breast cancer therapy. PI: J. Yan 02/23/2002 to 07/30/2012 NCI/NIH R01CA86412 20% effort, Direct Cost: $720,000 Title: Ligation of CR3 by Glucan and iC3b Links Innate and Adaptive Anti-tumor Immunity The major goal of this application is to understand how leukocyte CR3 is triggered for cytotoxicity by iC3b opsonized tumor cells in combination with yeast β(1,3)-D-glucan. The knowledge gained from these studies will lead to a novel form of tumor immunotherapy that stimulates phagocytes and NK cells to kill iC3b-opsonized tumors. PI: J. Yan 12/01/2010 to 05/30/2014 Kentucky Lung Cancer Research Program $150,000 Title: Combined Orally Administered Yeast-derived β-Glucan with 1650G Tumor Vaccine in the Treatment of NSCLC

Yan CV, 08-6-2014

7

The major goal of this proposal is to determine the adjuvant effect of β-glucan on lung cancer vaccine in mice and patients. PI: J. Yan 08/01/2010 to 7/31/2013 Alliance for Lupus Research $350,000 Title: Regulation of Autoreactive B Cells by Integrin ITGAM/CD11b The major goal of this proposal is to investigate the role of integrin CD11b in the regulation of autoreactive B cell activation and autoantibody production. PI: J. Yan 1/1/2011 to 5/30/2012 Mead Johnson Contracted Study $42,000 Title: Establishing non-clinical efficacy for the biological activity of bovine lactoferrin in infant formula in stimulating immune responses Co-I: J. Yan 3/01/2007 to 2/28/2012 RO1DK074720-01A1 (PI: M. Ratajczak) 5% effort Direct Cost: $1,000,000 Title: Novel Hematopoietic Effects of C3 Cleavage Fragments The major goal of this proposal is to understand the role of complement C3 and its cleavage fragments in hematopoiesis Co-I: J. Yan 07/01/2009-6/30/2012 1 R21 CA133668-01A2 (PI: LANE, ANDREW N) 5% effort Direct Cost: $250,000 Project Title: Stable isotopomer analysis of anabolic metabolic pathways in breast cancer

PI: J. Yan OGMB 081373 11/01/08 to 10/30/09 Kentucky Lung Cancer Research Program $50,000 Title: Lung Cancer Bio-immunotherapy using Particulate Beta-Glucan in combination with the Anti-VEGF Monoclonal Antibody Bevacizumab The major goal of this project is to determine the synergistic therapeutic effect of particulate β-glucan with bevacizumab in xenograft lung carcinoma models. PI: J. Yan University of Louisville Competitive Enhancement Grant 03/01/2007 to 02/29/2008 Direct Cost: $13,000 Title: Development of a Novel Immunotherapy for Breast Cancer

Yan CV, 08-6-2014

8

Co-PI: J. Yan James Graham Brown Cancer Center Pilot Project 03/01/2007 to 02/29/2008 Direct Cost: $50,000 Title: A Pilot Study of Immunological Effect of Beta-Glucan and Cetuximab in Lung Cancer Co-PI: J. YAN 08/01/05 to 07/31/06 James Graham Brown Cancer Center Pilot Grant Title: Phase II study of Rituximab plus beta-Glucan in patients with NHL, CLL, and SLL PI (sub-contractor): J. Yan 9/01/2006 to 8/31/2007 5% effort, Direct Cost: $100,000 NIH SBIR 1R43 AI071661-01 Title: Oral beta-glucan treats hematopoietic injury resulting from acute radiation exposure The major goal of this application is to evaluate the efficacy of particulate β-glucan in promoting multi-lineage hematopoietic regeneration and enhancing survival when orally administered after whole body radiation exposure. PI: J. Yan 03/1/04 to 02/28/09 10% effort, Direct Cost: $300,000 Kentucky Lung Cancer Research Program Title: Development of a Novel Immunotherapy for Lung Carcinoma The major goal of this proposal is to develop a novel strategy by targeting tumor antigens to B cells for breaking immune tolerance to tumor cells. PI: J. Yan 09/1/03 to 08/30/07 10% effort, Direct Cost: $375,000 American College of Rheumatology Investigator Award Title: The Induction of T cell Tolerance or Autoimmunity by Autoreactive B cells The major goal of this project is to delineate how autoreactive B cells regulate the autoreactive T cell tolerance or activation using murine lupus model. PI: J. Yan 07/1/02 to 06/30/06 S.L.E Foundation Total direct cost: $150,000 Title: Lymphocyte Activation and Tolerance in Autoantibody Transgenic Mice The major goal of this proposal is to examine the molecular processing of U1/Sm snRNP autoantigen in immunoglobulin transgenic animals on normal and autoimmune-prone background.

MENTORED AWARD: Dr. Chuanlin Ding 07/01/07 to 06/30/2010

Yan CV, 08-6-2014

9

Arthritis Foundation Postdoctoral Fellowship Total: $150,000 Title: Regulation of Autoreactive B Cells by Plasmacytoid Dendritic Cells

PATENTS:

US UTILITY PATENT APPLICATION: Anti-CD19 Composition and Methods for Treating Cancer (14/251,263) PROVISIONAL DISCLOSURE: Glucan Compositions and Methods of Enhancing CR3-dependent Neutrophil-mediated Cytotoxicity (US60/814,148) PROVISIONAL DISCLOSURE: Particulate β-glucan Compositions for Regulating Dendritic Cells (US60/841,795) PROVISIONAL DISCLOSURE: Membrane Complement Regulatory Protein (mCRPs) Antagonists and Their Uses (US60/841,849) PROVISIONAL DISCLOSURE: Combined β-Glucan with Avastin for Tumor Immunotherapy (US60/913,679)

EDITORIAL SERVICES (Peer Reviewer of Manuscripts)

Cancer Research Clinical Cancer Research Cancer Immunology Research Blood Leukemia Stem Cells FASEB Journal Nature Communications Journal of Immunology European Journal of Immunology Journal of Leukocyte Biology Clinical Immunology Journal of Biological Chemistry Cellular Immunology Applied Microbiology and Biotechnology Vaccine Experimental Hematology Cancer Letters Cancer Science Cancer Immunology, Immunotherapy Proceedings of the National Academy of Sciences, U.S.A OncoTarget PLosOne Journal of Translational Medicine

Yan CV, 08-6-2014

10

Journal of Infectious Diseases Human Immunology Journal of Lipid Research

Editorial Boards:

International Journal of Immunology and Immunotherapy World Journal of Stem Cells

ABSTRATS AND PRESENTATATIONS: Oral/Invited Presentations: National/International Meetings

1. Yan, J., Ma, B.L. 1996. Costimulatory molecule CD80 (B7-1) expressed on human tumor cell lines. Abstract book in The Advanced Course and Symposium in Immunology. pp.178, Oct. 1996, Beijing (oral presentation)

2. Yan, J., Ma, B.L., Liu, G.Z. 1996. Studies on the relationship between T cell activated signals and cytokines production. Abstract book in The Advanced Course and Symposium in Immunology. pp199, Oct. 1996, Beijing (oral presentation)

3. Yan, J., and Mamula, M. J. T and B cell tolerance and autoimmunity in anti-snRNP transgenic mice. International Conference on Immunology Specialized Forums on Antigen, Antigen-presenting cells and T cells. Shanghai, China. 1999. (Oral and poster presentation).

4. Yan, J., Shlomchik, MJ., and Mamula, MJ. B cells are necessary and sufficient to prime autoreactive T cells in vivo. American Association of Immunologists Annual meeting, Denver, CO. 2003

5. Ross GD., Allendorf, DJ., Baran, JT., Yan, J., Haribabu, B., and Lambris JD. Tumor regression mediated by glucan against iC3b-opsonized tumors requires CR3+ neutrophils recruited via C5a and leukotriene B4. American Association of Immunologists Annual meeting. Denver, CO. 2003 (oral and poster presentation).

6. Ross GD., Allendorf, DJ., Baran, JT., Yan, J., Haribabu, B., and Lambris JD. Tumor regression mediated by glucan against iC3b-opsonized tumors requires CR3+ neutrophils recruited via C5a and leukotriene B4. American Association of Immunologists Annual meeting. Denver, CO. 2003 (oral and poster presentation).

7. Yan, J., Ding, CL., and Mamula, MJ. Breaking anti-tumor T cell tolerance by targeting tumor antigen to B lymphocytes. American Association of Immunologists Annual meeting. Washington DC. 2004 (Oral and poster presentation).

8. Li Wang, C., Ding, H., Al-Gwahi, J., Marroquin, J., Yan. Toll-like Receptor Agonists Stimulate Autoreactive B Cells. 2005. Arthritis Foundation Research Conference, Atlanta, GA (Oral presentation).

9. Chuanlin Ding, L., Wang, H., Al-Gwahi, J., Marroquin1, R., Hansen, J., Yan. Targeting Antigen to B Cells Through CD19 Overcomes Immune Tolerance to Tumor Antigen Mucin 1 in MUC1 Transgenic Mice. American Association of Immunologists Annual meeting. San Diego, CA. 2005 (Oral and poster presentation).

10. Bing Li, Daniel Allendorf, Richard Hansen, Jose Marroquin, Daniel Cramer,

Yan CV, 08-6-2014

11

Claire Harris, Jun Yan. Importance of Decay Accelerating Factor (CD55) in Tumor Avoidance of Immune Destruction. American Association of Immunologists Annual meeting. Miami, FL. 2007 (oral presentation).

11. Jun Yan. Combined yeast β-glucan and anti-tumor mAb therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay accelerating factor (CD55). 4th Workshop on Complement Associated Diseases, Animal Models and Therapeutics. 2007. Greece (symposium presentation, 6/12/07)

12. Jun Yan. Plasmacytoid dendritic cells provide helper signal for autoreactive B cell activation. International Immunology Conference. 2007. Shanghai (symposium presentation, 7/14/07)

13. Jun Yan. The Role of B Lymphocytes in Autoimmunity and Tumor. Nankai University, Tianjin, China (7/18/2007)

14. Jun Yan. Nutritional Priming of Innate Immunity. Royal Society of Medicine, London, United Kingdom. 2007

15. Jun Yan. Glucan-mediated Innate Immune Responses. Mead Johnson Nutritional Company, Evansville, IN. 2008

16. Jun Yan. Glucan-mediated Tumor Immunotherapy. Wuhan University, Wuhan, China. 2009

17. Jun Yan. Role of B Cells in Autoimmunity and Cancer. Suzhou University, Suzhou, China. 2009

18. Jun Yan. Combined β-glucan with Anti-tumor mAbs for Cancer Immunotherapy. Southern Illinois University School of Medicine. 2009.

19. Jun Yan. Effect of Yeast-derived β-Glucan in conjunction with Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models. BIT Life Sciences' 7th Annual Congress of International Drug Discovery Sciences & Technology-2009 Shanghai. China

20. Jun Yan. β-Glucan-mediated Tumor Immunotherapy. University of Kentucky, Lexington. April, 2010.

21. Jun Yan. Complement Regulatory Protein in Cancer Therapy. Cell-Based Assays. San Francisco, CA. Oct 4-5. 2010

22. Jun Yan. Pivotal Role of γδ T Cells in Psoriasis Pathogenesis. Shanghai Jiaotong University School of Medicine, Shanghai, China. Nov 8. 2010

23. Jun Yan. B Cell Autoimmunity in Lupus Pathogenesis. Suzhou University School of Medicine, Suzhou, China. March 3, 2011.

24. Jun Yan. β-Glucan-mediated Tumor Immunotherapy. National Taiwan University, Taiwan, China. May 18, 2011

25. Jun Yan. β-Glucan-mediated Hematopoietic Progenitor/Stem Cell Mobilization. The First Baltic Sea Stem Cell Meeting, Szczecin, Poland. May 28. 2011

26. Jun Yan. Pivotal Role of IL-17-producing γδ T Cells in Skin Inflammation. Sino-US Immunology Conference, Changsha, China. August 4, 2011.

27. Jun Yan. Decorating Tumor Cells with Pathogen Components:β-Glucan-mediated Tumor Immunotherapy. Research!Louisville, Oct 10, 2011

28. Jun Yan. β-Glucan-mediated Tumor Immunotherapy. MD Anderson Cancer Center, Oct 18, 2011

Yan CV, 08-6-2014

12

29. Jun Yan. Tumor Immunotherapy. Shanghai Ruijin Hospital. Nov 7, 2011 30. Jun Yan. Role of dermal γδ T cells in skin inflammation. Suchoow University

School of Medicine. Nov 14, 2011 31. Jun Yan. β-Glucan-mediated Tumor Immunotherapy: Recognizing Tumor Cells

as Pathogens by Immune Cells. Northwest University, Dec 12, 2011 32. Jun Yan. β-Glucan-mediated Immunotherapy in Cancer. University of Missouri

Cancer Center. March 20, 2012 33. Jun Yan. Negative Regulation of Autoreactive B Cell Activation by Integrin

CD11b Molecule. Alliance for Lupus Research Meeting. New York, May 11, 2012 34. Jun Yan. Translational Research Prospective. Tsinghua University, Beijing,

China. May 29, 2012 35. Jun Yan. Role of IL-1β Signaling Pathway in the Regulation of Dermal γδ T

Cells. 9th International Conference on Innate Immunity. Rhodes, Greece. June 25, 2012

36. Jun Yan. Pivotal Role of Dermal γδ T Cells in the Pathogenesis of Psoriasis. The Third International Conference on Regulatory T Cells and Th Subsets and Clinical Application in Human Diseases. Shanghai, China. Oct 13. 2012

37. Jun Yan. β-Glucan-mediated Tumor Immunotherapy. Saint Louis University. Dec 18, 2012.

38. Jun Yan. Dermal γδT Cells- A New Player in Psoriasis Pathogenesis. Boehringer Ingelheim. Danbury, CT. Feb 27. 2013.

39. Jun Yan. β-Glucan, A Potent Adjuvant to Engage both Innate and Adaptive Immunity. Vaccine And Gene Therapy Institute of Florida Corp. April 10, 2013.

40. Jun Yan. β-Glucan-mediated Tumor Immunotherapy-Engaging Innate Immune Cells. Columbus, Ohio State University. April 23, 2013.

Poster Presentations: National/International Meetings:

41. Yan, J., Vetvika, V., Ross, G.D. 1998. Requirement for natural anti-tumor

antibodies (NtAb) for b-glucan therapy of murine mammary carcinoma. FASEB J. 12:A278. (poster presentation)

42. Yan, J., and Mamula, MJ. T cell autoimmunity in autoantibody transgenic mice. Keystone meeting. 2001 (poster presentation).

43. Yan, J., and Mamula, MJ. The regulation of T cell autoimmunity and tolerance in B cell transgenic mice. Lupus Foundation Forum. 2002 (poster presentation).

44. Yan, J., Shlomchik, MJ., and Mamula, MJ. Targeting tumor antigen to B cells breaks anti-tumor T cell tolerance. New England Immunology Conference. 2002 (poster presentation).

45. Yan., Shlomchik, MJ., and Mamula, MJ. B cells are necessary and sufficient to prime autoreactive T cells in vivo. The FESEB Journal. 2003 (oral and poster presentation).

46. Ross GD., Allendorf, DJ., Baran, JT., Yan, J., Haribabu, B., and Lambris JD. Tumor regression mediated by glucan against iC3b-opsonized tumors requires CR3+ neutrophils recruited via C5a and leukotriene B4. The FASEB Journal.

Yan CV, 08-6-2014

13

2003 (oral and poster presentation). 47. Allendorf, DJ., Baran, JT., Hansen RD., Hong, F., Marroquin, J., Yan, J., Walsh,

D., and Ross, GD. Macrophages shuttle orally administrated glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models. The FASEB Journal. 2003 (poster presentation).

48. Yan, J., Ding, CL., and Mamula, MJ. Breaking anti-tumor T cell tolerance by targeting tumor antigen to B lymphocytes. The FASEB Journal. 2004 (Oral and poster presentation).

49. Allendorf D.J. Hansen R.D., Yan J., Baran J.T., Ross G.D. Macrophage processing of large triple helix-folded beta glucan produces a smaller single-chain beta glucan that functions to prime neutrophil CR3 and mediate regression of Ab and iC3b-opsonized tumors. Molecular Immunology 2004. 41:203

50. Ross G.D., Yan J., Hansen R.D., Allendorf D.J., Brandley B. Beta glucans augment the function of anti-tumor monoclonal antibodies (mAbs) by providing a novel mechanism for killing tumors via circulating blood neutrophils. 2004. International Society for Biological Therapy of Cancer.

51. Chuanlin Ding, L., Wang, H., Al-Gwahi, J., Marroquin1, R., Hansen, J., Yan. Targeting Antigen to B Cells Through CD19 Overcomes Immune Tolerance to Tumor Antigen Mucin 1 in MUC1 Transgenic Mice. FASEB Journal. 2005 (Oral and poster presentation).

52. Li Wang, C., Ding, H., Al-Gwahi, J., Marroquin, J., Yan. Toll-like receptor agonists stimulate “tolerogenic” anti-snRNP B cells for activation. FASEB Journal. 2005 (Oral and poster presentation).

53. D. E. Cramer, D. J. Allendorf, M. Z. Ratajczak, R. D. Hansen, G. D. Ross, J. Yan. Beta-glucan Enhancement of Complement Mediated Hematopoietic Recovery after Bone Marrow Injury. FASEB Journal. 2005

54. D. J. Allendorf, R., Hansen, J., Marroquin, B., Li, G., Ross, and J., Yan. PGG-Betafectin, a soluble β(1,3: 1,6) glucan, is processed by macrophages into an active moiety capable of priming neutrophil CR3 (CD11b) for cytotoxicity against iC3b- and monoclonal antibody-opsonized tumors. 2005. AACR meeting Abstract book.

55. Li Wang, C., Ding, H., Al-Gwahi, J., Marroquin, J., Yan. Toll-like Receptor Agonists Stimulate Autoreactive B Cells. 2005. Arthritis Foundation Research Conference (Oral presentation).

56. J., Yan, Daniel Allendorf, Bing Li, Richard Hansen. Beta-Glucans augment the killing activity of anti-tumor monoclonal antibodies by providing a novel mechanism that primes neutrophil CR3 to kill antibody targeted tumor cells. 2005. Era of Hope Department of Defense Breast Cancer Research Program meeting.

57. Reca R., Kucia M., Baran J., Yan J., Ratajczak M. Defective engraftment of HSPC from C3aR-/- mice reveals an underappreciated role of C3a-C3aR axis in stem cell homing to bone marrow. 2005. American Society of Hematology meeting.

58. Chuanlin Ding, Li Wang, Jose Marroquin, Daoxin Wang, Jun Yan. Interaction between pDC and autoreactive B cells in murine lupus model. 2006 American Association of Immunogists.

59. Li B, Allendorf A, Hansen R, Marroquin J, Ding, CL, Cramer D, and Jun Yan.

Yan CV, 08-6-2014

14

Yeast beta-glucan amplifiers phagocyte killing of iC3b-opsonized tumor cells via Complement receptor 3-Syk-PI3-Kinase pathway. 2006. American Association of Immunogists.

60. Cramer D, Li B, Ratajczak M, Hansen R, and Jun Yan. Soluble beta-glucan induces stem cell mobilization. 2006. American Association of Immunologists.

61. Yan J, Li B, Marroquin J. Yesast beta-glucan PGG was processed by macrophage to release active moiety for priming neutrophils. 2006. American Association for Cancer Research.

62. Carolina Salvador, Bing Li, Richard Hansen, Daniel Cramer, Jun Yan. Cytotoxicity of Bevacizumab is enhanced by β-glucan in tumors expressing membrane-bound VEGF. 2007. American Society of Clinical Oncology.

63. Bing Li, Daniel Allendorf, Richard Hansen, Daniel Cramer, Jun Yan. C5a mediated neutrophil chemotaxis in combined yeast β-glucan and anti-tumor immunotherapy is potentiated by regulation of the DAF (CD55). 2007. American Association for Cancer Research. Los Angeles, CA.

64. Chuanling Ding, Li Wang, Hayma Al-Gwahi, Jose Marroquin, Richard Hansen, Jun Yan. T and B Cell Immune Responses to Tumor Antigen MUC1 are Induced by Targeting Antigen to B Lymphocytes. 2007. American Association of Immunologists. Miami, FL.

65. Bing Li, Daniel Allendorf, Richard Hansen, Jose Marroquin, Daniel Cramer, Claire Harris, Jun Yan. Importance of Decay Accelerating Factor (CD55) in Tumor Avoidance of Immune Destruction. 2007. American Association of Immunologists (oral presentation). Miami, FL.

66. Daniel Cramer, Stephanie Wagner, Bing Li, Jingjing Liu, Richard Hansen, Ryan Reca, Mariusz Ratajczak, Jun Yan. Beta-Glucan Induced Mobilization of Hematopoietic Stem Cells Requires Matrix Metalloproteinase-9. 2007. American Association of Immunologists. Miami, FL.

67. Chuanlin Ding, Li Wang, Yihua Cai, Thomas Tedder, Suzanne Ildstad, Jun Yan. Plasmacytoid dendritic cells provide helper signal for autoreactive B cell activation. International Immunology Conference. 2007. Shanghai (symposium and poster presentation, 7/14/07), China.

68. Hong Xu, Jun Yan, Yiming Huang, Paula M. Chilton, Michael K Tanner, Lala-Rukh Hussain and Suzanne T. Ildstad. CD154 blockade prevents allosensitization through inhibiting both T and B-cell activation and decreasing expression of IFN-g and IL-10 in T-cells. 49th American Society of Hematology meeting. December 8-11, 2007. Georgia World Congress Center, Atlanta, Georgia.

69. Hong Xu, Jun Yan, and Suzanne T. Ildstad. CD154:CD40 Co-stimulatory Blockade: A Specific Approach to Prevent Sensitization to Donor Alloantigens. 49th American Society of Hematology meeting. December 8-11, 2007. Georgia World Congress Center, Atlanta, Georgia.

70. Huang, Y., Kucia, M., Atay, S., Hussain, L.R., Xu, H., Yan, J., Ratajczak, M.Z., and Ildstad, S.T.: Bone marrow transplantation temporarily improves the function of pancreas in streptozotocin-induced diabetes XXII International Congress of The Transplantation Society, Sydney, Australia, August 10-14, 2008 (Oral Presentation).

Yan CV, 08-6-2014

15

71. Xu, H., Huang, Y., Hussain, L-R, Yan, J., and Ildstad, S.T.: Blockade of CD154:CD40 co-stimulatory molecule interactions prevents sensitization to alloantigen. The American Transplant Congress, May 31-June 4, 2008, Toronto, Ontario, Canada (Poster Presentation).

72. Ding CL., Wang L., Marroquin J., and Yan J. Activation of Autoreactive B cells by Interaction with CpG-stimulated Plasmacytoid Dendritic Cells. AAI San Diego 2008

73. Yan J., Particular Glucans Modulates Tumor Microenvironment Toward Th1 Responses. 2008 World Congress of Cancer, Shanghai, China (Symposium Talk)

74. Hong Xu, Ziqiang Zhu, Lala-Rukh Hussain, Yiming Huang, Larry D. Bozulic, Jun Yan and Suzanne T. Ildstad. Immune-based non-myeloablative conditioning to establish mixed chimerism and donor-specific tolerance: Targeting adaptive T and B cell responses. 50th ASH Annual Meeting, San Francisco, CA. Dec 6-9, 2008

75. Ding CL and Jun Yan. Full Activation of Autoreactive B Cells Requires Helper Signals from Plasmacytoid Dendritic Cells. AAI meeting, Seattle. 2009

76. Ding CL, Cai, YH, and Jun Yan. Dominant epitope p21-40 of snRNP D protein recognized by both autoreactive T and B cells in lupus-prone MRL lpr/lpr mice. AAI meeting 2010. Baltimore.

77. Gunn, L., Cai, YH, Hu, XL., Ding, CL., Qi, CJ., Hansen, R., Jun Yan. Role of Complement Activation Component C5a on Tumor Progression AAI meeting 2010. Baltimore.

78. Ding CL and Jun Yan. Role of Intergrin CD11b Molecule in the Regulation of Autoreactive B Cells. AAI meeting 2011. San Francisco.

79. Cai YH and Jun Yan. Pivotal Role of Dermal γδ T Cells in the Pathogenesis of Psoriasis. AAI meeting 2011. San Francisco.

80. Gunn L and Jun Yan. Tumor Microenvironment Modulated by Complement Component C5a. AAI meeting 2011. San Francisco.

PUBLICATIONS Articles published in Peer-Reviewed Journals:

1. Liu M, Luo F, Albeituni S, Hu X, Ma Y, Ding C, Cai Y, Sanders MA, Jain D,

Kloecker G, Bousamra M, Zhang HG, Lin X, Tan J, Lorkiewicz P, Higashi R, Lane AN, Fan TWM, and Yan J. Natural Product β-Glucan Converts Immunosuppressive Macrophages in Mice and Humans. In revision.

2. Sellers K, Fox M, Bousamra M, Slone S, Higashi R, Miller DM, Wang Y, Yan J, Yuneva M, Lane A, Fan TW. 2014. Pyruvate Carboxylase Is Critical in Human Non-Small Cell Lung Cancer. Journal of Clinical Investigation. In press

3. Hudson SV, Huang JS, Yin W, Albeituni S, Rush J, Khanal A, Yan J, Ceresa B,

Frieboes HB, McNally LR. 2014. Targeted Non-invasive Imaging of EGFR-expressing Orthotopic Pancreatic Cancer using Multispectral Optoacoustic Tomography (MSOT). Cancer Research. 74(21):6271-9.

Yan CV, 08-6-2014

16

4. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, Chen Z,

Wang K, Zhang T, Xu J, Han Y, Zhang T, Wu X, Wang J, Gong W, Zheng S, Qiu F, Yan J* and Huang J*. 2014. γδT17 Cells Promotes the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer. Immunity. 00147-2. doi: 10.1016/j.immuni (*Corresponding authors)

5. Cai Y, Xue F, Fleming C, Yang J, Ding C, Ma Y, Liu M, Zhang HG, Zheng J, Xiong N, and Yan J. 2014. Differential Developmental Requirement for Dermal IL-17-producing Vγ4 and Vγ6 T Cells and Their Peripheral Regulation in Health and Skin Inflammation. Nature Communications. 5:3986. DOI: 10.1038/ncomms4986

6. Yan J, Kloecker G, Fleming C, Hansen R, Hu X, Ding C, Cai Y, Dong X, Donninger

H, Eaton JW, Clark G. 2014. Human Polymorphonuclear Neutrophils Specifically Recognize Tumor Cells for Killing. OncoImmunology. e950163 DOI:10.4161/15384101.2014.950163

7. Yan J, and Huang J. 2014. Innate γδT17 Cells Convert Cancer-elicited Inflammation

into Immunosuppression through Myeloid-derived Suppressor Cells. OncoImmunology. e953423 DOI:10.4161/21624011.2014.953423

8. Jiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, Mu J, Zhang L, Wang B, Yan J, Miller D, Zhang HG. Restoration of miR17/20a in Solid Tumors Enhances the Natural Killer Cells Antitumor Activity by Targeting Mekk2. Cancer Immunology Research. May 6. PMID: 24801835

9. Jiang H, Wang P, Wang Q, Mu J, Zhang L, Wang B, Yan J, Miller D, Zhang HG.

2014. Quantitatively Controlling Expression of miR-17-92 Determines Colon Tumor Progression in A Mouse Tumor Model. American Journal of Pathology. 184:1355-68

10. Wang S, Zhou H, Feng T, Wu R, Sun X, Guan N, Qu L, Gao Z, Yan J, Xu N, Zhao J,

Qi C. 2014. β-Glucan Attenuates Inflammatory Responses in Oxidized LDL-induced THP-1 Cells via the p38 MAPK Pathway. Nutrition, Metabolism & Cardiovascular Diseases. 24:248-55

11. Mu J, Zhuang X, Wang Q, Jiang H, Deng ZB, Wang B, Zhang L, Kakar S, Yan J,

Miller D, Zhang HG. 2014. Interspecies Communications between Plant and Mouse Gut Host Cells Through Edible Plant-derived Exosome-like Nanoparticles. Molecular Nutrition Food Research. Doi: 10.1002/mnfr.201300729

12. Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Kloecker G, Zhang HG, and Yan J.

Targeting of Antigens to B Lymphocytes via CD19 As A Means for Tumor Vaccine Development. Journal of Immunology. 190(11):5588-99. 2013

Yan CV, 08-6-2014

17

13. Ding C, Ma Y, Chen X, Liu M, Cai Y, Hu X, Xiang D, Nath S, Zhang HG, Ye H, Powell D, and Yan J. Integrin CD11b Negatively Regulates BCR Signaling to Maintain Autoreactive B Cell Tolerance. Nature Communications. 4:2813. doi: 10.1038/ncomms3813. 2013.

14. Albeituni S, Ding C, and Yan J. Hampering the Immune Suppressor: Therapeutic

Targeting of Myeloid-derived Suppressor Cells (MDSC) in Cancer. The Cancer Journal. 19(6):490-501. 2013.

15. Wang Q, Zhuang X, Mu J, Deng Z, Jiang H, Xiang X, Wang B, Yan J, Miller D,

Zhang HG. A Grapefruit-derived Nano Vector Enables Multi-model Strategies to Deliver Therapeutic Agents. Nature Communications. 4:1867. doi: 10.1038/ncomms2886. 2013

16. Wang B, Zhuang X, Deng ZB, Jiang H, Mu J, Wang Q, Xiang X, Guo H, Zhang L,

Dryden G, Yan J, Miller D, Zhang HG. 2013. Targeted Drug Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released from Grapefruit. Molecular Therapy. Auguest 13. Doi: 10.1038/mo. PMID:23939022

17. Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, Yan J, Lu L, Xu H, Wang S. β-

Glucan Enhances Anti-tumor Immune Responses by Regulating Differentiation and Function of Monocytic Myeloid-derived Suppressor Cells. European Journal of Immunology. 43(5):1220-30. 2013.

18. Wu X, Chen X, Zhou Q, Li P, Yu B, Li J, Qu Y, Yan J, Yu Y, Yan M, Zhu Z, Liu B, Su L. Hepatocyte Growth Factor Activates Tumor Stromal Fibroblasts to Promote Tumorigenesis in Gastric Cancer. Cancer Letters. 335:128-35 PMID: 23402812. 2013.

19. Cai, Y.H., Fleming, C., and Yan, J.: Dermal γδT Cells- A New Player in the Psoriasis Pathogenesis. International Immunopharmacology. 16(3):388-91. 2013. PMID:23499509

20. Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B,

Zhang L, Roth M, Welti R, Mobley J, Yan J, Miller D, Zhang HG. Grape Exosome-like Nanoparticles Induce Intestinal Stems Cells and Protect Mice from DSS-Induced Colitis. Molecular Therapy. 21(7):1345-57. 2013

21. Yu B, Chen X, Li J, Qu Y, Su L, Peng Y, Huang J, Yan J, Yu Y, Gu Q, Zhu Z, Liu B.

Stromal Fibroblasts in the Microenvironment of Gastric Carcinoma Promotes Tumor Metastasis via Upregulating TGALN Expression. BMC Cell Biology. 14:17. doi: 10.1186/1471-2121-14-17. 2013.

22. Deng ZB , Ju S, Zhuang X, Xiang X, Mu J, Hong J, Zhang L, Mobley J , McClain C,

Yan J, Miller DM, Kronenberg M, Zhang HG. Intestinal Mucus Exosome-like Nanoparticles Carry Prostaglandin E2 and Suppress Activation of Liver Natural Killer

Yan CV, 08-6-2014

18

T Cells. Journal of Immunology. 190(7):3579-89. 2013.

23. Deng, ZB., Zhuang, X., Ju, S., Xiang, X., Mu, J., Wang, Q., Hong, J., Zhang, L., Kronenberg, M., Yan, J., Miller, D., and Zhang, HG. Intestinal Mucus-derived Nanoparticles Mediate Activation of Wnt/β-catenin Signaling Plays a Role in Induction of Liver NKT Cell Anergy. Hepatology. 57(3):1250-61. 2013. PMID:22991247

24. Albeituni, S., and Yan, J.: The Effects of β-Glucans on Dendritic Cells and Implications for Cancer Therapy. Anti-cancer Agents in Medicinal Chemistry. 13(5):689-98. 2013. PMID:23092290

25. Gunn, L., Ding, CL., Liu, M., Ma, YF., Qi, CJ., Cai, YH., Hu, XL., Aggarwal, D.,

Zhang, HG., and Yan J.: Opposing Roles for Complement Component C5a in Tumor Progression and the Tumor Microenvironment. Journal of Immunology. 189(6):2985-94. 2012.

26. Xiang, D., Sharma, V.R., Freter, C.E., and Yan, J.: Anti-tumor Monoclonal Antibodies in Conjunction with β-Glucans: a Novel Anti-Cancer Immunotherapy. Current Medicinal Chemistry. 19(25):4298-305. PMID:22834812. 2012.

27. Xu, H.,*, Yan, J., *, Huang, YM., Chilton, PM., Ding, CL., Schanie, CL., and Ildstad,

ST. TLR4/TRIF Pathway Controls Innate Immune Cell-mediated Rejection for Allogeneic Bone Marrow Cells. Cell Transplantation. In press (*co-first author) 2012. PMID:23146386

28. Xiang X, Deng Z, Zhuang X, Ju S, Mu J, Jiang H, Zhang L, Yan J, Miller D, Zhang

HG. Grhl2 Determines the Epithelial Phenotype of Breast Cancers and Promotes Tumor Progression. PLoS One. 7(12):e50781. 2012. PMID:23284647

29. Tian J, Ma J, Ma K, Ma B, Tang X, Baidoo SE, Tong J, Yan J, Lu L, Xu H, Wang S.

Up-Regulation of GITRL on Dendritic Cells by WGP Improves Anti-Tumor Immunity in Murine Lewis Lung Carcinoma. PLoS One. 7(10):e46936. 2012.

30. Yaddanapudi, K., Mitchell, RA., Putty, K., Willer, S., Sharma, RK., Yan, J.,

Bodduluri, H., Eaton, JW.: Vaccination with Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible? PLos One. 7:e42289. 2012.

31. Cai, YH., Fleming, C., and Yan J.: New Insights of T Cells in the Pathogenesis of

Psoriasis. Cellular and Molecule Immunology. 9(4):302-9. 2012.

Yan CV, 08-6-2014

19

32. Xu H., Zhu Z., Huang Y., Bozulic LD., Hussain L., Yan J., Ildstad ST. Innate as well as Adaptive Immune Responses Are Tolerized in Chimeras Prepared with Non-Myeloablative Conditioning. Transplantation. 15;93(5):469-76. 2012.

33. Deng Z, Cheng Z, Xiang X, Yan J, Zhuang X, Liu C, Jiang H, Ju S, Zhang L, Grizzle

W, Mobley J, Roman J, Miller D, Zhang HG. Tumor Cell Cross Talk with Tumor-Associated Leukocytes Leads to Induction of Tumor Exosomal Fibronectin and Promotes Tumor Progression. American Journal of Pathology. 180(1):390-8. 2012.

34. Cai, YH., Shen, XY., Ding, CL., Qi, CJ., Li, KJ., Li, X., Jala, VR., Zhang, HG., Wang,

T., Zheng, J., and Yan J.: Pivotal Role of Dermal IL-17-producing γδ T Cells in Skin Inflammation. Immunity. 35(4):596-610. 2011.

35. Qi, C., Cai, YH., Gunn, L., Ding, CL., Li, B., Kloecker, G., Qian, K., Vasilakos, J., Saijo, S., Iwakura, Y., Yannelli, JR., and Yan J.: Differential Pathways Regulating Innate and Adaptive Anti-tumor Immune Responses by Particulate and Soluble Yeast-derived β-Glucans. Blood. 117(25):6825-36. 2011.

36. Tian, J., Ma, J., Wang, S*., Yan, J*., Chen, J., Tong, J., Wu, C, Liu, Y., Ma, B., Mao, C., Jiao, Z., Shao, Q., Lu, L., Xu, H.: Increased expression of mGITRL on D2SC/1 cells by particulate β-glucan impairs the suppressive effect of CD4+CD25+ regulatory T cells and enhances the effector T cell proliferation. Cellular Immunology, 270:183-7. 2011. * co-corresponding author

37. Fan, TW., Lane, AN., Higashi, R., and Yan J.: Stable Isotope Resolved Metabolomics

of Lung Cancer in a SCID Mouse Model. Metabolomics. 1;7(2):257-269. 2011.

38. Kong M., and Yan, J.: Modeling and Testing Treated Tumor Growth Using Cubic Smoothing Splines. Biometrical Journal, 53(4):595-613. 2011.

39. Lane, AN., Fan, TW., Bousamra, M., Higashi, R., Yan, J., Miller, DM.: Clinical Applications of Stable Isotope-resolved Metabolomics (SIRM) in Non-Small Cell Lung Cancer. OMICS: A Journal of Integrative Biology, 15(3):173-82, 2011.

40. Li, B., Cai, YH., Qi, CJ., Hansen, R., Ding, CL., Mitchell, TC., and Yan J.: Orally Administrated Particular β-Glucan Modulates Tumor-capturing Dendritic Cells and Improves Anti-tumor T Cell Responses in Cancer. Clinical Cancer Research, 16(21):5153-64, 2010.

41. Huang YM, Kucia M, Hussain L, Wen Y, Xu H, Yan J, Ratajczak MZ, and Ildstad ST.: Bone Marrow Transplantation Temporarily Improves Pancreatic Function in Streptozotocin-Induced Diabetes: Potential Involvement of Very Small Embryonic-Like Cells. Transplantation. 89(6):677-85, 2010.

42. Xu, H., Huang YM., Hussain L, Ding CL., Yan J., and Ildstad ST.: Sensitization to

Yan CV, 08-6-2014

20

minor antigens is a significant barrier in bone marrow transplantation and is prevented by CD154:CD40 blockade. American Journal of Transplantation. 10(7):1569-79, 2010.

43. Goga L, Perez-Abadia G, Pushpakumar S, Cramer D, Yan J, Todnem N, Anderson G,

Soni C, Barker J, Maldonado C.: 2010. Cell Membrane Modification for Rapid Display of Bi-Functional Peptides: A Novel Approach to Reduce Complement Activation. The Open Cardiovascular Medicine Journal. 4:157-165. PMCID: 2948132

44. Ding C, Cai Y, Marroquin J, Ildstad ST, Yan J.: Plasmacytoid Dendritic Cells

Regulate Autoreactive B Cell Activation via Soluble Factors and in a Cell-to-Cell Contact Manner. Journal of Immunology. 183(11):7140-9, 2009.

45. Zhong WJ., Hansen R, Li B., Cai Y, Salvador C., Moore GD., Yan J.: Effect of Yeast-derived β-Glucan in conjunction with Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models. Journal of Immunotherapy 32(7):703-12, 2009.

46. Ma YF, Chen HD, Wang QL, Luo FL, Yan J, and Zhang XL. IL-24 stimulates early

neutrophils to produce Th1 cytokines, subsequently activating CD8+ T cells for defense against Salmonella typhimurium infection. European Journal of Immunology Dec;39(12):3357-68, 2009.

47. Driscoll M, Hansen R, Ding C, Cramer DE, Yan, J.: Therapeutic Potential of Various β-Glucan Sources in Conjunction with Anti-Tumor Monoclonal Antibody in Cancer Therapy. Cancer Biology & Therapy, 3:8(3):216-223, 2009.

48. Liu J, Gunn L, Li B, Hansen R, Yan, J.: Combined Yeast-derived β-Glucan and Anti-

tumor Monoclonal Antibody for Cancer Immunotherapy. Experimental and Molecular Pathology. 86:208-214, 2009.

49. Liu J, Gunn L, Hansen R, Yan, J.: Yeast-derived β-Glucan in Combination with Anti-

tumor Monoclonal Antibody Therapy in Cancer. Current Patents on Anti-cancer Drug Discovery. 4:101-109, 2009.

50. Tan Y, Li Y, Xiao J, Shao S, Ding C, Arteel GE, Webster KA, Yan J, Yu H, Lu Cai

L, and Li X. A Novel CXCR4 Antagonist Derived from Human SDF-1β Enhances Angiogenesis in Ischemic Mice. Cardiovascular Research, 82:513-521, 2009.

51. *Ding CL, Wang L, Marroquin J, Yan, J.: Targeting of Antigens to B Cells Augments

Antigen-specific T Cell Responses and Breaks Immune Tolerance to Tumor-associated Antigen MUC1. Blood 112(7):2817-25, 2008.

Yan CV, 08-6-2014

21

52. Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R.: The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol. 632:159-74, 2008.

53. Xu, H., Huang, Y., Chilton, P.M., Hussain, L.R., Tanner, M.K., Yan, J., and Ildstad,

S.T.: Strategic nonmyeloablative conditioning: CD154:CD40 co-stimulatory blockade at primary BMT promotes engraftment for secondary BMT after engraftment failure. Journal of Immunology 181(9):6616-24, 2008.

54. Cramer, DE, Wagner, S, Li, B, Liu, J., Hansen, R., Reca, R., Wu, W., Zuba-Surma, E.,

Lamber, D., Ratajczak, MZ, Yan, J.: Mobilization of Hematopoietic Progenitor Cells by Yeast-derived β-Glucan Requires Activation of Matrix Metalloproteinase-9. Stem Cells, 26(5):1231-40, 2008.

55. Salvador, C., Li, B., Hansen, R., Cramer, D., Kong, M., Yan, J.: Yeast-derived β-

Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models. Clinical Cancer Research, 14(4):1239-1247, 2008.

56. Xu, H., * Yan, J., * Huang, YM., Chilton, PM., Ding, CL., Schanie, CL., Wang, L.,

Ildstad ST.: Co-stimulatory blockade of CD154:CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization. Blood, 111(6):3266-75, 2008. (* two authors contributed equally)

57. *Li, B., Allendorf, D., Hansen, R., Marroquin, J., Cramer, D.E., Harris, C.L., Yan, J.:

Combined Yeast β-Glucan and Anti-tumor mAb Therapy Require C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay Accelerating Factor CD55. Cancer Research. 67(15):7421-7430, 2007.

58. Li B, Cramer D, Wagner S, Hansen R, King C, Kakar S, Ding C, Yan J.: Yeast glucan

particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clinical Immunology. 124(2):170-81, 2007.

59. Xu H, Chilton PM, Huang Y, Schanie CL, Yan J, Ildstad ST.: Addition of

cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation. Transplantation. 15;83(7):954-63, 2007.

60. Ding C, Yan J.: Regulation of autoreactive B cells: checkpoints and activation. Arch

Immunol Ther Exp (Warsz). 55(2):83-9, 2007.

61. Reca R, Cramer D, Yan J, Laughlin MJ, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. : A Novel Role of Complement in Mobilization; Immunodeficient Mice

Yan CV, 08-6-2014

22

are Poor G-Csf Mobilizers because they Lack Complement-Activating immunoglobulins. Stem Cells. 25(12):3093-100, 2007.

62. Xu H, Yan J, Ildstad ST.: Xenotransplantation: a step closer to reality? (commentary)

Blood. 110:3815, 2007. 63. Yan, J., Gee, RJ., Shlomchik, MJ., Mamula, MJ.: B Cells Drive Early T Cell

Autoimmunity in vivo Prior to Dendritic Cells-mediated Autoantigen Presentation. Journal of Immunology. 177:4481-4487, 2006.

64. Ding C*., Wang L*., Al-Ghawi H., Marroquin J., Mamula M., Yan J.: Toll-like Receptor Engagement Stimulates Anti-snRNP Autoreactive B Cells for Activation. (*co-first author). European Journal of Immunology. 36:2013-2024, 2006.

65. Li, B., Allendorf, D., Hansen, R., Marroquin, J., Ding, C., Cramer, D., and Yan, J.:

Yeast β-Glucan Amplifies Phagocyte Killing of iC3b-opsonized Tumor Cells via CR3-Syk-PI3-kinase Pathway. Journal of Immunology, 177:1661-1669, 2006.

66. *Cramer D., Allendorf D., Baran J., Hansen R., Ratajczak J., Ratajczak M., Yan,

J.: Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood. 107:835-840, 2006.

67. Ratajczak MZ., Reca R., Wysoczynski M., Yan J., Ratajczak J.: Modulation of the

SDF-1-CXCR4 axis by the third complement component (C3) – Implications for trafficking of CXCR4+ stem cells. Experimental Hematology. 34:986-995, 2006.

68. Reca R, Wysoczynski M, Yan J, Lambris JD, Ratajczak MZ.: The role of third

complement component (C3) in homing of hematopoietic stem/progenitor cells into bone marrow. Adv Exp Med Biol. 586:35-51, 2006.

69. Xu, H., Chilton, P., Tanner, M., Huang, Y., Schanie, C., Dy-Liacco, M., Yan, J.,

Ildstad, ST.: Humoral Immunity is the Dominant Barrier for Allogeneic Bone Marrow Engraftment in Sensitized Recipients. Blood. 108:3611-9, 2006.

70. Yan, J., M. Wolff, J. Unternaehrer, I. Mellman, and M.J. Mamula.: Antigen

directed to CD19 on B cells efficiently activates T cells. Int’l Immunol, 17:869-77, 2005.

71. Yan, J., Allendorf, DJ., Brandley, B.: Yeast WGP β-Glucan in Conjunction with

Anti-tumor Monoclonal Antibodies to Treat Cancer. Expert Opin Biol Ther. 5:691-702, 2005.

72. Allendorf, DJ., Yan, J., Ross, GD., Hansen, RD., Baran, JT., Subbarao, K., Wang,

L., Haribabu, B.: C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis

Yan CV, 08-6-2014

23

is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor mAb and β-Glucan (Corresponding author) Journal of Immunology. 174:7050-7056, 2005.

73. Hong F., Yan J., Baran J., Allendorf D., Hansen R., Ostroff G., Xing P., Cheung

N., Ross GD.: Mechanism by which orally administered β(1,3) Glucans enhance the tumoricidal activity of anti-tumor monoclonal antibodies in murine tumor models. Journal of Immunology. 173:797-806, 2004.

74. Liang FT., Yan J., Mbow ML., Sviat SL., Gilmore RD., Mamula M., Fikrig E.:

Borrelia burgdorferi changes its surface antigenic expression in response to immune attack. Infection and Immunity. 72:5759-67, 2004.

75. Hong F., Hansen R., Yan J., Allendorf D., Baran J., Ostroff G., Ross GD.: β-

Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Research. 63:9023-31, 2003.

76. Anderson B., McNiff J., Yan J., Doyle HA., Mamula MJ., Shlomchik MJ.,

Shlomchik WD.: Memory CD4 T cells do not induce graft-versus-host disease. Journal of Clinical Investigation. 112:101-108, 2003.

77. Wang, T., Scully, E., Yin, Z., Kim H., Wang S., Yan J., Mamula, MJ., Anderson

JF., Craft, J., and Fikrig E.: IFN-γ T cells help control murine West Nile virus infection. Journal of Immunology. 171:2524 – 2531, 2003.

78. Yan, J., and Mamula MJ.: B and T cell tolerance and autoimmunity in

autoantibody transgenic mice. International. Immunology. 14: 963 –971, 2002.

79. Yan, J. and Mamula MJ.: Autoreactive T cell revealed in the normal repertoire: escape from negative selection and peripheral tolerance. Journal of Immunology. 168: 3188-3194, 2002.

80. Doyle HA., J. Yan, B. Liang and M.J. Mamula.: Lupus autoantigens: their origins,

forms, and presentation. Immunological Research. 24: 59-65, 2001.

81. Yan, J., Vectvika, V., Mayadas, T.N., Ross, G.D.: Critical role of Kupffer cell CR3 in the clearance of soluble β-glucan or C3-opsonized erythrocytes. Immunopharmacology. 46:39-54, 2000.

82. Yan, J., V. Vectvika, Y. Xia, A. Coxon, M.C. Carroll, T.N. Mayadas, and G.D.

Ross.: Soluble β-glucan, a “specific” biological response modifier that targets C3-opsonized tumors in vivo for cytotoxic activation of leukocyte CR3. Journal of Immunology. 163:3045-3052, 1999.

Yan CV, 08-6-2014

24

83. Xia Y., Vetvicka V., Yan J., Hanikyrova M., Mayadas T., Ross GD.: The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of Immunology. 162(4): 2281-90, 1999.

84. Ross GD., Vetvicka V., Yan J., Xia Y., Vetvickova J.: Therapeutic intervention

with complement and β-glucan in cancer. Immunopharmacology. 42:61-74, 1999.

85. Yan, J., Ma, B., Guo, X., Sun, Y., Zhang, J., Zhang, H.: CD80 (B7-1) expression on human tumor cell lines and its costimulatory signals for T cell proliferation and cytokine production. Chin. Med. J. 111:269-71, 1998. PMID: 10374432

86. Zhou, J., Yan, J., and Ma, BL.: The Preparation of Monoclonal Antibody Against

Cell Membrane by Cyclophosphamide. Progress in Microbiology and Immunology. 3:1-3, 2000.

87. Zhou, J., Ma, BL., Yan, J., Zhang, JY., Zhang, HM.: The Production of

Monoclonal Antibody to CD80 by Subtractive Immunization Techniques and Identification of its Biological Activity. Chinese Journal of Immunology. 16(1), 2000.

88. Yan, J., Ma, BL. Effect of Costimulatory Molecule CD80 (B7-1) on T Cell

Activation. Chinese Journal of Immunology. 13(4):196-199, 1997.

89. Yan, J., Ma, B.L., Zhang, JY., Zhang, HM., Wang, S.Y., Sun, Y.: Surface Marker Changes on the Pre- and Post- CD80 (B7-1)-transfected Human Tumor Cell Lines. Chin. J. Tumor Biother. 9:20-24, 1997.

90. Yan, J., Yao, M., Xia, S., Shao, QX., Liu, GZ., Huang, YS., Ma, BL.: Effect of

Lipid Angiogenic Factor on Epidermal Skin Cell Cycle in Wound Healing. Chinese Journal of Biochemical Pharmaceutics. 05, 1997.

91. Shao, QX, Yan, J., Xia, S.: Effect of Lipid Angiogenic Factor on Cytokine

Production by Lymphocytes. Immunological Journal. 04, 1997.

92. Xu, HX., Wang, SJ., Yan, J., Pan, ZC., Xia, S., Liu, GZ.: Isolation and Characterization of Human Dendritic Cells from Peripheral Blood. Immunological Journal. 03:20-24, 1997.

93. Yan, J., Liu GZ., and Ma, BL.: Current Progress on Gene Therapy for Disease

Treatment. Foreign Medicine: Molecular Biology. 18(2):51-53, 1996.

94. Yan, J., Xia, S., Shao, Q.X.: Extraction and Purification of Lipid Angiogeneic Factor. Chinese Journal of Biochemical Pharmaceutics. 16:2-4, 1996.

Yan CV, 08-6-2014

25

95. Yan, J., and Ma, BL. Progress on Costimulatory Molecules CD80 and CD86. Foreign Medicine: Immunology. 4, 1995.

96. Yan, J., Liu, G.Z., Xu, H.X.: Studies on the Mechanisms Involved in the Dendritic

Cell Antigen Presentation. Immunological Journal. 03, 1994.

97. Yan, J., Liu, G.Z., Xu, H.X.: Cytokines Production involved in the Dendritic Cell Antigen Presentation. J. Zhenjiang Med. Col. 1:1-4, 1994.

98. Yan, J., Yao, K., Zhou, YX.: Molecular Basis of T Cell Activation Signaling

Transduction. Foreign Medicine: Immunology. 04, 1993.

99. Yan, J., Yao, K., Zhou, Y.X.: The Relationship Among T Cell Activation, Activated Signals and IFN-γ Production. Immunological Journal. 8(2):95-98, 1992.